SCHEMBL2900966

SCHEMBL2900966

ClO/N=C\c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
PLA2G7 Q13093 2/20 0.48
NOX1 Q9Y5S8 1/20 0.41
GAA P10253 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GRIN2D O15399 2/20 0.40
GRIN3B O60391 2/20 0.40
GRIN1 Q05586 2/20 0.40
GRIN2A Q12879 2/20 0.40
GRIN2B Q13224 2/20 0.40
GRIN2C Q14957 2/20 0.40
GRIN3A Q8TCU5 2/20 0.40
TAAR1 Q96RJ0 1/20 0.40
HDAC3 O15379 1/20 0.39
TNKS O95271 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1797266 1.00 LMNA (0.52) LMNAL3MBTL1PLA2G7NOX1GAA
SCHEMBL1797264 1.00 LMNA (0.52) LMNAL3MBTL1PLA2G7NOX1GAA
SCHEMBL11100359 0.87 MAPT (0.46) LMNAL3MBTL1PLA2G7GAANPC1
SCHEMBL9709937 0.79 LMNA (0.57) LMNAL3MBTL1PLA2G7NOX1GAA
SCHEMBL11097349 0.78 MAOB (0.54) LMNAL3MBTL1GRIN2DGRIN3BGRIN1
SCHEMBL11097351 0.78 MAOB (0.54) LMNAL3MBTL1GRIN2DGRIN3BGRIN1
SCHEMBL3455168 0.78 NPC1 (0.45) LMNAGAANPC1RAB9ASMN1; SMN2
SCHEMBL4719950 0.76 PLA2G7 (0.47) PLA2G7NPC1RAB9ASMN1; SMN2GRIN2D
SCHEMBL28618284 0.76 ALDH1A1 (0.50) LMNAL3MBTL1GAAKMT2AMAPT
SCHEMBL28605730 0.76 CHRM5 (0.64) GAANPC1RAB9ASMN1; SMN2GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790759-B2 Glycyrrhetinic acid-30-amide derivatives and their use TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) 2010-09-07 US disclosed
EP-1935892-B1 GLYCYRRHETINIC ACID-30-AMIDE DERIVATIVES AND THE USES THEREOF TIANJIN INST PHARM RESEARCH (CN) 2010-08-11 EP disclosed
US-20080214636-A1 Glycyrrhetinic Acid-30-Amide Derivatives and Their Use TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) 2008-09-04 US disclosed
EP-1935892-A1 GLYCYRRHETINIC ACID-30-AMIDE DERIVATIVES AND THE USES THEREOF TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214636-A1 Glycyrrhetinic Acid-30-Amide Derivatives and Their Use IL36G, CYP26A1, IL17A LMNA 3220/4885L3MBTL1 4690/4885PLA2G7 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.